Cullinan Therapeutics, INC Form 4 insider transactions

Cullinan Therapeutics reports insider transactions involving common stock and stock options by Chief Scientific Officer Jennifer Michaelson.

Jacquelyn Sumer, Chief Legal Officer at Cullinan Therapeutics, Inc., reported the acquisition of 2,470 shares of common stock through the company's Employee Stock Purchase Plan.

Cullinan Therapeutics' Chief Financial Officer, Mary Kay Fenton, has acquired 1,541 shares of common stock through the company's Employee Stock Purchase Plan.

Cullinan Therapeutics director Anthony Rosenberg acquired stock options for 25,319 shares of common stock.

David D. Meek, a director at Cullinan Therapeutics, Inc., acquired stock options for 25,319 shares of common stock on June 16, 2026.

Cullinan Therapeutics, Inc. reports that Director Mary Thistle acquired stock options for 25,319 shares of common stock.

Cullinan Therapeutics, Inc. reports that Director Mittie Doyle was granted stock options for 21,781 shares.

Chief Scientific Officer Jennifer Michaelson exercised options and sold 8,000 shares of Cullinan Therapeutics common stock.

Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, sold 1,780 shares of common stock at a weighted average price of $14.14, executed under a pre-established 10b5-1 trading plan.

Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, reported sales of common stock totaling 5,353 shares.

Cullinan Therapeutics' President and CEO, Nadim Ahmed, sold 13,515 shares of common stock to cover personal income tax obligations related to restricted stock unit vesting.

Cullinan Therapeutics' Chief Medical Officer, Jeffrey Alan Jones, sold 4,582 shares of common stock to cover tax obligations.

Cullinan Therapeutics' Chief Legal Officer, Jacquelyn L. Sumer, reported a planned sale of 3,601 common shares to cover tax obligations.

Cullinan Therapeutics' Chief Medical Officer, Jeffrey Alan Jones, sold 4,982 shares of common stock at $13.62 per share on February 20, 2026, to cover personal income tax obligations.

Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, reported the exercise of stock options and subsequent sale of common stock, including shares to cover tax obligations.

Cullinan Therapeutics' Chief Legal Officer, Jacquelyn L. Sumer, sold 3,742 shares of common stock to cover tax obligations related to vested restricted stock units.

Cullinan Therapeutics' President and CEO, Nadim Ahmed, sold 16,381 shares of common stock to cover personal income tax obligations related to restricted stock unit vesting.

Cullinan Therapeutics' CFO, Mary Kay Fenton, sold 4,398 shares of common stock at $13.62 per share to cover tax obligations related to vested restricted stock units.

Cullinan Therapeutics' Chief Legal Officer, Jacquelyn L. Sumer, was granted 230,000 stock options with an exercise price of $12.44, vesting over four years.

Cullinan Therapeutics' Chief Medical Officer, Jeffrey Alan Jones, was granted 300,000 stock options with an exercise price of $12.44, vesting over four years.

Cullinan Therapeutics' President and CEO, Nadim Ahmed, was granted 828,000 stock options with an exercise price of $12.44, vesting over four years.

Cullinan Therapeutics' Chief Business Officer, Corrine Savill, was granted 175,000 stock options with an exercise price of $12.44, vesting over four years.

Cullinan Therapeutics' Chief Financial Officer, Mary Kay Fenton, acquired 68,750 restricted stock units and 137,500 stock options as part of her compensation.

Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, acquired 57,500 shares of common stock and 115,000 stock options.

Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, sold 416 shares of common stock at $12.03 per share to cover tax obligations related to restricted stock unit vesting.

Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, reported the sale of 4,000 shares of common stock at $12.30 per share, executed under a pre-arranged 10b5-1 trading plan.

Cullinan Therapeutics' Chief Financial Officer, Mary Kay Fenton, acquired 27 shares of common stock through the company's Employee Stock Purchase Plan.

Cullinan Therapeutics' President and CEO, Nadim Ahmed, sold 9,922 shares of common stock at $10.01 per share to cover personal income tax obligations related to restricted stock unit vesting.

Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, sold 1,345 shares of common stock for $10.01 per share under a pre-arranged 10b5-1 trading plan.

Cullinan Therapeutics' Chief Legal Officer, Jacquelyn L Sumer, sold 3,480 shares of common stock at $9.67 per share to cover tax obligations related to restricted stock unit vesting.